CHICAGO, March 23, 2011 /PRNewswire/ -- Available at ICAP Ocean Tomo's Spring 2011 Live IP Auction, this patent portfolio discloses methods and techniques related to patch-based drug delivery and monitoring.
Administering drugs orally or by injection each has inherent problems. Orally administered drugs (e.g., tablets or pills) pass through the patient's digestive system which breaks down the drug into its constituting components and flushes the rest of the compound out of the body. Consequently, only a small percentage of the administered medicine enters the patient's circulatory system, limiting the drug's effectiveness. This also means that a relatively large intake of medicine is required for effective treatment. Yet, a large dose may adversely affect the patient's digestive system. This can cause many anomalies and harmful side effects.
Drug delivery by injection can be more effective. However, conventional injections may cause pain, require close medical supervision, and add the potential risk of infections. Furthermore, injected medicines cannot be controlled or withdrawn from the body if any adverse effects are observed. In the case of animals, these drug delivery techniques are often risky due to possible aggressive reflex actions during administration of the drug. For these reasons, a safe, controlled and effective alternative method using a transmucosal patch has inherent advantages.
Key Characteristics & Benefits
This patent lot discloses the following:
- Advanced techniques for delivering drugs through mucosal surface or body tissues of a patient (i.e. human or animal), such as the mouth.
- This transmucosal drug delivery technique utilizes a medication device (e.g., gum pad) that comprises a semi-permeable package or a tablet matrix containing a prescribed amount of therapeutic medicine.
- The device also comprises a muco-adhesive portion that assists in attaching the device to body surface (e.g., gums) so that the outer semi-permeable layer is in constant touch with the target mucosal surface for a sufficient time as to allow thorough absorption of the encapsulated medicine by the patient's body.
- Once the device is attached to the target surface, saliva enters through the semi-permeable outer layer and dissolves the stored medicine. This forms a solution that passes towards the mucosal tissues and is directly absorbed into the body's circulatory system.
- This facilitates faster and more effective treatment of various diseases.
- Structural features (i.e., porosity and layer thickness) of the device can be varied to facilitate a controlled release of medicine over a specified time period.
- This lot also discloses specific drug compositions for treating migraines and a non-invasive technique for measuring/monitoring the blood levels in mammals by attaching a device to their mucosal surface or body tissues.
- These techniques enable convenient administration of drugs to both human and animal patients, minimizing the risks of dangerous accidents possible with conventional oral or injection based drug delivery techniques.
- Furthermore, the innovative techniques described may reduce costs associated with veterinarian care as these do not require the procedural costs of a traditional visit.
- The patents in this lot have been cited by many research institutions as well as industrial giants, such as University of Minnesota, Cephalon and L'Oreal.
This lot should be of interest to pharmaceutical companies, biotechnology firms, healthcare service providers, and entities involved in drug manufacturing and administration.
- The global market for drug delivery systems is expected to reach $196.4 billion by 2014, while the global market for transmucosal drug delivery systems alone was around $2 billion in 2010. (1)(2)
To learn more about the assets available for sale in this portfolio:
Contact Dean Becker of ICAP Ocean Tomo at Dean.Becker@us.icap.com
About ICAP Ocean Tomo LLC
ICAP Ocean Tomo is the intellectual property brokerage division of ICAP and the world's premier patent auction firm.
ICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to www.icap.com.
SOURCE ICAP Ocean Tomo